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Abstract
Objective. To evaluate the effect of adding DPP4 inhibitor (DPP4-i) on glycemic variability (GV) in patients with type 2 
diabetes mellitus (T2DM) treated with premixed human insulin (MHI). 
Methodology. We conducted a prospective study in patients with T2DM on twice-daily MHI with or without metformin 
therapy. Blinded continuous glucose monitoring was performed at baseline and following 6 weeks of Vildagliptin therapy.
Results. Twelve patients with mean (SD) age of 55.8 (13.1) years and duration of disease of 14.0 (6.6) years were 
recruited. The addition of Vildagliptin significantly reduced GV indices (mmol/L): SD from 2.73 (IQR 2.12-3.66) to 2.11 
(1.76-2.55), p=0.015; mean amplitude of glycemic excursions (MAGE) 6.94(2.61) to 5.72 (1.87), p=0.018 and CV 34.05 
(8.76) to 28.19 (5.36), p=0.010. In addition, % time in range (3.9-10 mmol/l) improved from 61.17 (20.50) to 79.67 
(15.33)%, p=0.001; % time above range reduced from 32.92 (23.99) to 18.50 (15.62)%, p=0.016; with reduction in AUC 
for hyperglycemia from 1.24 (1.31) to 0.47 (0.71) mmol/day, p=0.015. Hypoglycemic events were infrequent and the 
reduction in time below range and AUC for hypoglycemia did not reach statistical significance. 
Conclusion. The addition of DPP4-I to commonly prescribed twice-daily MHI in patients with T2DM improves GV and 
warrants further exploration.
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INTRODUCTION 
Glycemic variability (GV) has become an emerging target 
for optimal glycemic control in patients with diabetes 
independent of HbA1c.1-3 Recent studies have highlighted 
the association of GV to hypoglycemia and its associated 
adverse consequences.4-6 In addition, there are increasing 
data in the literature supporting association of GV to 
microvascular and macrovascular diabetic complications 
although definitive evidence on hard clinical outcomes 
remains limited.1,6-9 Nonetheless, with the advent of 
continuous glucose monitoring (CGM), the focus of 
glycemic management in diabetes has moved beyond 
HbA1c to include reduction of GV and hypoglycemic 
events. 
Type 2 diabetes mellitus (T2DM) is a progressive disease 
and many patients will require insulin therapy in order 
to achieve glycemic control. In Asia, premixed insulin, 
often in combination with metformin, is commonly used 
for the treatment of T2DM.10,11 While more convenient 
for the patients, premixed insulin with a fixed ratio of 
prandial and intermediate insulin is less flexible and may 
be associated with more hypoglycemic risk and greater 
GV. In addition, in resource-limited countries and public 
institutions, premixed human insulin is still commonly 
prescribed. Premixed human insulin may further increase 
the GV compared to premixed insulin analogues due to 
its less physiological pharmacokinetic profile.12,13 Hence, 
a strategy to reduce GV in patients on premixed human 
insulin is highly desired. 
Incretin-based therapies especially the dipeptidyl 
peptidase 4 inhibitors (DPP4-i) have been increasingly 
used for the treatment of T2DM. Few studies have shown 
DPP4-i to be effective in reducing GV in patients treated 
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* Data from this study was submitted to The Endocrine Society's annual meeting 2020 (San Francisco) and had been accepted for poster presentation. The meeting was 
cancelled due to the COVID-19 pandemic. The abstract of the study was published in the Journal of the Endocrine Society Vol 4(Supplement 1) May 2020: A396-7.
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